-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $10

Benzinga·11/16/2026 12:18:43
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $15 to $10.